EPA

If you take fish oil, eat salmon, or want to know whether your heart attack risk is being quietly raised by something diet alone hasn't fixed, this is the number to know. Higher blood EPA is linked to fewer heart attacks, fewer revascularizations, lower colorectal cancer risk, and lower overall mortality in large human studies.

A standard lipid panel can look fine while your EPA sits at a level that leaves real residual cardiovascular risk on the table. This test measures the actual amount of EPA circulating in your blood, so you can see where you stand, not guess from how often you eat fish.

What EPA Is and Where It Comes From

EPA (eicosapentaenoic acid) is a 20-carbon omega-3 polyunsaturated fat. You get it mainly from oily fish and fish oil, with smaller amounts converted by your body from plant-based omega-3s. Once in your bloodstream, EPA gets built into the outer layer of your cells, where it shapes how those cells handle inflammation, clotting, and cholesterol traffic.

Inside your body, EPA serves as a raw material for signaling molecules that help shut down inflammation (called specialized pro-resolving mediators), competes with a pro-inflammatory fat called arachidonic acid, and changes how cholesterol-carrying particles behave. Higher EPA is associated with better function of the lining of your blood vessels, more stable arterial plaques, and lower triglycerides.

Heart Attack and Cardiovascular Disease Risk

This is where the evidence is strongest. In a pooled analysis of 17 cohorts tracking 42,466 people for a median of 16 years, those in the highest fifth of long-chain omega-3 blood levels (a group of fats that includes EPA, DPA, and DHA together) had roughly 15 to 18 percent lower all-cause mortality and 13 to 21 percent lower cardiovascular mortality than those in the lowest fifth, after adjusting for standard risk factors. The protective signal is for long-chain omega-3s collectively rather than EPA alone.

In a meta-analysis pooling 67 cohorts and 310,955 participants, higher marine omega-3 biomarker levels were linked to lower risk of coronary heart disease and total cardiovascular disease, with the relative risk for EPA specifically around 0.85 and for DHA around 0.70. In the INSPIRE biobank of 987 patients followed about 10 years, those in the top quarter of plasma EPA had a major cardiovascular event hazard ratio of 0.36 (about 64 percent lower risk) compared to the bottom quarter, after full adjustment for age, sex, and comorbidities.

In Japan's Hisayama Study (3,103 adults), people with both elevated hs-CRP (high-sensitivity C-reactive protein, a marker of inflammation) and a lower ratio of EPA to arachidonic acid had about 52 percent higher cardiovascular risk for each 0.20 drop in that ratio. What this means for you: if your inflammation is up and your EPA is low, the two stack on top of each other.

The Role of the EPA to DHA Balance

EPA does not work in isolation. There is a hypothesis, not yet a proven mechanism, that DHA, its sister omega-3, can blunt EPA's protective effect when DHA runs disproportionately high. In one observational study of 987 people, higher DHA appeared to reduce the protective impact of higher EPA on major cardiovascular events, and an EPA-to-DHA ratio of one or higher was tied to lower 10-year event rates (27 percent vs 37 percent). Major cardiology reviews note there is no established biological mechanism for this effect, so the finding should be treated as suggestive rather than settled. What this means for you: a simple "more omega-3 is better" framing may miss the point, and composition is worth tracking alongside the total.

Colorectal Cancer

A dose-response meta-analysis pooling prospective cohorts found that higher circulating EPA was associated with lower risk of incident colorectal cancer after multivariable adjustment. The association is graded: more EPA in your blood, less risk on the curve.

Heart Failure

In the MESA study of 6,562 adults, higher plasma EPA was significantly associated with lower risk of incident heart failure (hazard ratio 0.73, 95% confidence interval 0.60 to 0.91), including both reduced and preserved ejection fraction subtypes. Heart failure is one of the conditions most consistently linked to oxidative stress, and EPA helps blunt that stress in human supplementation trials.

Prostate Cancer

In 157 men with low-risk prostate cancer on active surveillance, higher levels of EPA inside the prostate tissue itself were associated with lower odds of having high-grade disease. This is tissue-level data, but it suggests EPA's role goes beyond cardiovascular outcomes.

Mood and Migraine

For depression, the evidence is mixed and the overall quality is rated as poor. A 2021 Cochrane review found only a small benefit for predominantly EPA formulations, with substantial variation between studies, and trials using solely EPA did not reach statistical significance. A separate meta-analysis did find benefit for EPA-dominant products (at least 60 percent EPA, around 1 to 2 grams per day), so EPA-rich formulations may help some people, but the certainty is low. For migraine, a single 12-week randomized trial in 70 adults with episodic migraine found that 1.8 grams per day of EPA reduced monthly migraine days, severity, disability, and improved mood and quality of life, with no major adverse events. The result is promising but comes from one small study and needs replication.

Metabolic Health: A Mixed Signal

The metabolic syndrome data are less consistent than the cardiovascular data. In one analysis of the Guangzhou Nutrition and Health Study using a DHA-to-EPA ratio, a higher DHA-to-EPA ratio was associated with lower risk of developing metabolic syndrome. However, earlier analyses from the same cohort actually found that higher erythrocyte EPA and total omega-3s were associated with lower metabolic syndrome risk, not higher. The picture is unsettled.

This doesn't make EPA a "bad number." It reinforces the lesson from the cardiovascular data: EPA is best interpreted in context with DHA and your broader metabolic picture, not as a standalone score where higher is automatically better. The cardiovascular benefit signal is strong and consistent; the metabolic syndrome signal is a reminder that ratios and overall context matter.

Where Your Number Likely Sits

In NHANES 2011 to 2012, the average serum EPA in US adults was 0.61 percent of total fatty acids, with children lower at 0.28 percent. In over 1.1 million US clinical samples, median plasma EPA was about 22 micrograms per milliliter (a very small concentration in blood). Women and adults 65 and older had EPA levels meaningfully higher than younger adults, partly reflecting decades of diet and partly age-related metabolic differences. Roughly 95 percent of US children and 68 percent of US adults fall below the dietary intake levels that match higher protective EPA blood levels.

The Omega-3 Index, in Context

This test measures EPA specifically. A related and complementary measurement, the Omega-3 Index, sums EPA plus DHA in red blood cells. Research from a meta-analysis of 10 cohort studies suggests that getting Omega-3 Index levels into the higher range (8 percent or above) is associated with roughly 30 percent lower risk of fatal coronary heart disease compared with very low levels (around 4 percent). EPA alone tracks with this story but is more directly informative about the omega-3 most tied to acute cardiovascular event reduction in trials of purified EPA.

Why a Single Reading Is Not Enough

EPA in your blood is a moving target. It rises within weeks to months when you eat more oily fish or start a quality omega-3 supplement, and falls when intake drops. A one-time number tells you a snapshot; a trend tells you whether your intake actually produces the blood level you want, and whether that level holds steady over years.

Get a baseline, retest in 3 to 4 months if you start or change a fish oil regimen or significantly shift your diet, then at least annually thereafter. The same dose of fish oil produces very different blood levels in different people because of differences in absorption, supplement form (triglyceride forms raise levels more than ethyl ester forms per gram), and background diet. Going by label dose without checking the blood level is how people end up over- or under-supplemented for years.

When Results Can Be Misleading

• Recent fish meal or fish oil dose: plasma EPA reflects recent intake more than long-term status. A salmon dinner the night before testing can transiently lift your number above your true average. Aim to test at a consistent time relative to your usual diet and supplement schedule.
• Supplement form differences: triglyceride-based fish oils raise blood EPA more per gram than ethyl ester forms. If you switched products between tests, a difference in your number may reflect bioavailability rather than how much you took.
• Lab-to-lab variability: small differences in how labs measure fatty acids produce meaningful shifts in reported values. Tracking your trend is most reliable when you stick with one lab and one assay method.
• Genetic differences in fatty acid metabolism: people with certain FADS gene variants accumulate much less EPA from any given dose, particularly in populations of Mexican and other ancestry. A low number may reflect biology, not just intake.

What to Do With an Out-of-Pattern Result

If your EPA is low, the practical next move is to look at the full omega-3 picture: ideally an Omega-3 Index (EPA plus DHA) and the EPA to arachidonic acid ratio, alongside triglycerides, hs-CRP, and ApoB (apolipoprotein B, a measure of atherogenic particles). Low EPA in someone with elevated triglycerides or elevated hs-CRP carries more residual cardiovascular risk than low EPA alone, and that combination changes how aggressively you would push intake or consider prescription EPA with your physician.

If your EPA is high but your overall metabolic markers (fasting glucose, triglycerides, waist circumference) are off, that is the cue to look at the DHA-to-EPA balance and broader diet, not to dismiss the metabolic signals. A cardiology or lipidology referral is reasonable if you have established cardiovascular disease, persistently high triglycerides, or a strong family history and your EPA stays low despite intake changes; this is the population where high-dose prescription EPA has shown its largest event-reduction benefit in randomized trials.